Gold L, Back T, Arnold G, Dreier J, Einhäupl K M, Reuter U, Dirnagl U
Department of Neurology, Charité Hospital, Humboldt University, Berlin, Germany.
Brain Res. 1998 Feb 9;783(2):188-93. doi: 10.1016/s0006-8993(97)01341-3.
We investigated whether the vasoactive neurotransmitter serotonin (5-HT) is involved in cortical spreading depression (CSD)-associated hyperemia in the rat. We focused on the 5-HT2 receptor, which is engaged in 5-HT induced small arteriolar relaxation in cats, as well as on the 5-HT1D/1B receptor, the binding site of the potent antimigraine drug sumatriptan. In male barbiturate anaesthetized Wistar rats (n=25) CSDs were elicited by brain topical application of 1 M KCl, and the DC-potential and regional cerebral blood flow (rCBF, by Laser Doppler flowmetry) were measured over the same hemisphere through dura and thinned bone, respectively. Intravenous application of 8 mg/kg of the 5-HT2A/2C receptor antagonist ritanserin (group I; n=8) significantly reduced the hyperperfusion amplitude during CSD by approximately 44% (p<0.05, from 342+/-124 to 194+/-97%, baseline before CSD=100%), and prolonged its duration by approx. 30%. Vehicle alone (group II; n=4) did not affect CSD hyperperfusion. The highly selective 5-HT1D/1B receptor agonist 311C90 was given in two doses: 100 micrograms/kg i.v. (n=5) had no effect on CSD hyperperfusion, while 800 micrograms/kg (n=5) increased hyperperfusion significantly (p<0.05, from 224+/-86 to 310+/-148%). We conclude that serotonin is, probably via 5-HT2 receptors, involved in the modulation of the regional cerebral blood flow increase during CSD. Novel highly selective receptor antagonists may help to discriminate the differential contribution of various 5-HT receptor subspecies.
我们研究了血管活性神经递质5-羟色胺(5-HT)是否参与大鼠皮质扩散性抑制(CSD)相关的充血过程。我们重点关注5-HT2受体,它参与猫体内5-HT诱导的小动脉舒张,同时也关注5-HT1D/1B受体,它是强效抗偏头痛药物舒马曲坦的结合位点。在雄性巴比妥麻醉的Wistar大鼠(n = 25)中,通过脑表面应用1 M KCl诱导CSD,分别通过硬脑膜和变薄的颅骨在同一半球测量直流电位和局部脑血流(rCBF,采用激光多普勒血流仪)。静脉注射8 mg/kg的5-HT2A/2C受体拮抗剂利坦色林(I组;n = 8)可使CSD期间的高灌注幅度显著降低约44%(p < 0.05,从342±124降至194±97%,CSD前基线 = 100%),并使其持续时间延长约30%。单独给予溶剂(II组;n = 4)对CSD高灌注无影响。高选择性5-HT1D/1B受体激动剂311C90分两种剂量给药:静脉注射100 μg/kg(n = 5)对CSD高灌注无影响,而800 μg/kg(n = 5)可使高灌注显著增加(p < 0.05,从224±86升至310±148%)。我们得出结论,5-羟色胺可能通过5-HT2受体参与CSD期间局部脑血流增加的调节。新型高选择性受体拮抗剂可能有助于区分各种5-HT受体亚型的不同作用。